Role of carnitine esters in brain neuropathology

Molecular Aspects of Medicine

Volumn 25, Issue 5-6, 2004, Pages 533-549

  Virmani, Ashraf ^a   Binienda, Zbigniew ^b  

^a Scientific Affairs   (Italy)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Acetyl L carnitine; Brain; Cell; FFA; L Carnitine; Mitochondria

Indexed keywords

7 NITROINDAZOLE; ACYLCARNITINE; ALPHA TOCOPHEROL; ANTIOXIDANT; CARNITINE; CATALASE; MELATONIN; NITRIC OXIDE SYNTHASE INHIBITOR; PIVAMPICILLIN; SELENIUM; VALPROIC ACID;

ALLOXAN DIABETES MELLITUS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATTENTION DEFICIT DISORDER; BIOAVAILABILITY; BRAIN DISEASE; CARNITINE DEFICIENCY; CELL FUNCTION; CELL MEMBRANE; CEREBELLAR ATAXIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; DIABETIC NEPHROPATHY; DOWN SYNDROME; EPILEPSY; FRAGILE X SYNDROME; HUMAN; HUNTINGTON CHOREA; LIVER TOXICITY; MENTAL DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; ORGANIC BRAIN SYNDROME; PANCREATITIS; PARKINSON DISEASE; REVIEW; REYE SYNDROME; STREPTOZOCIN DIABETES; STROKE;

BRAIN; CARNITINE; CELL MEMBRANE; CLINICAL TRIALS; ESTERS; HUMANS; NEURONS;

MAMMALIA;

EID: 4444289045     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2004.06.003     Document Type: Review

References (96)

1. Ames B.N. The metabolic tune-up: metabolic harmony and disease prevention. J. Nutr. 133:2003;1544S-1548S
2. Arduini A., Denisova N., Virmani M.A., Avrova N., Federici G., Arrigoni-Martelli E. Evidence for the involvement of carnitine-dependent long-chain acyltransferases in neuronal triacylglycerol and phospholipid fatty acid turnover. J. Neurochem. 62:1994;1530-1538
3. Arienti G., Ramacci M.T., Maccari F., Casu A., Corazzi L. Acetyl-L-carnitine influences the fluidity of brain microsomes and of liposomes made of rat brain microsomal lipid extracts. Neurochem. Res. 17:1992;671-675
4. Arrigo A., Casale R., Buonocore M., Ciano C. Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency. Int. J. Clin. Pharmacol. Res. 10:1990;133-137
5. Ater S.B., Swinyard E.A., Tolman K.G., Madsen J.A., Matsuo F. Effects of SKF525A, phenobarbital, fasting, and carnitine on the anticonvulsant activity and neurotoxicity of valproate in mice. Epilepsia. 25:1984;599-604
6. Bahl J.J., Bressler R. The pharmacology of carnitine. Ann. Rev. Pharmacol. Toxicol. 27:1987;257-277
7. Bahring R., Standhardt H., Martelli E.A., Grantyn R. GABA-activated chloride currents of postnatal mouse retinal ganglion cells are blocked by acetylcholine and acetylcarnitine: how specific are ion channels in immature neurons? Eur. J. Neurosci. 6:1994;1089-1099
8. Barrett A.M. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology. 56:2001;425
9. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53:2003;S39-47
10. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Strivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192
11. Bertamini M., Marzani B., Guarneri R., Guarneri P., Bigini P., Mennini T., Curti D. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur. J. Neurosci. 16:2002;2291-2296
12. Binienda Z., Ali S.F. Neuroprotective role of L-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicol. Lett. 125:2001;67-73
13. Binienda Z., Virmani A. The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. Curr. Med. Chem. - Central Nervous System Agents. 3:2003;275-282
14. Binienda Z., Frederick D.L., Ferguson S.A., Rountree R.L., Paule M.G., Schmued L., Ali S.F., Slikker W. Jr., Scallet A.C. The effects of perinatal hypoxia on the behavioral, neurochemical, and neurohistological toxicity of the metabolic inhibitor 3-nitropropionic acid. Metab. Brain Dis. 10:1995;269-282
15. Binienda Z., Johnson J.R., Tyler-Hashemi A.A., Rountree R.L., Sapienza P.P., Ali S.F., Kim C.S. Protective effect of L-carnitine in the neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA). Ann. N.Y. Acad. Sci. 890:1999;173-178
16. Blokland A., Bothmer J., Honig W., Jolles J. Behavioural and biochemical effects of acute central metabolic inhibition: effects of acetyl-L-carnitine. Eur. J. Pharmacol. 235:1993;275-281
17. Brass E.P. Carnitine Transport. Ferrari R., DiMauro S., Sherwood G. L-Carnitine and its Role in Medicine: From Function to Therapy. 1992;21-36 Academic Press Limited, London
18. Bresolin N., Freddo L., Vergani L., Angelini C. Carnitine, carnitine acyltransferases, and rat brain function. Exp. Neurol. 78:1982;285-292
19. Brouillet E., Hantraye P., Ferrante R.J., et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movement in primates. Proc. Natl. Acad. Sci. USA. 92:1995;7105-7109
20. Bodis-Wollner I., Chung E., Ghilardi M.F., Glover A., Onofrj M., Pasik P., Samson Y. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neural Transm. Park. Dis. Dement. Sect. 3:1991;63-72
21. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., Yankner B.A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 33:2002;677-688
22. Brenninstall G.N. Carnitine deficiency syndromes. Pediatr. Neurol. 6:1990;75-81
23. Caprioli A., Markowska A.L., Olton D.S. Acetyl-L-carnitine: chronic treatment improves spatial acquisition in a new environment in aged rats. J. Gerontol. A - Biol. Sci. Med. Sci. 50:1995;B232-236
24. Cereda G., Scolari M. Effect of an energy stimulator on the performance of a group of young people: evaluation by a video-game test. Acta Vitaminol. Enzymol. 6:1984;63-68
25. Chavez E., Pena A., Zazueta C., Ramirez J., Garcia N., Carrillo R. Inactivation of mitochondrial permeability transition pore by octylguanidine and octylamine. J. Bioenerg. Biomembr. 32:2000;193-198
26. De Angelis C., Scarfo C., Falcinelli M., Perna E., Reda E., Ramacci M.T., Angelucci L. Acetyl-L-carnitine prevents age-dependent structural alterations in rat peripheral nerves and promotes regeneration following sciatic nerve injury in young and senescent rats. Exp. Neurol. 128:1994;103-114
27. De Grandis D., Minardi C. Acetyl-L-carnitine (levoacetylcarnitine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R. D. 3:2002;223-231
28. De Falco F.A., D'Angelo E., Grimaldi G., Scafuro F., Sachez F., Caruso G. Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome. Clin. Ter. 144:1994;123-127
29. DeVivo D.C., Tein I. Primary and secondary disorders of carnitine metabolism. Int. Pediatr. 5:1990;134-141
30. Dhitavat S., Ortiz D., Shea T.B., Rivera E.R. Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem. Res. 27:2002;501-505
31. 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 23:2003;5928-5935
32. Evangeliou A., Vlassopoulos D. Carnitine metabolism and deficit - when supplementation is necessary? Curr. Pharm. Biotechnol. 4:2003;211-219
33. Famularo G., Moretti S., Marcellini S., Trinchieri V., Tzantzoglou S., Santini G., Longo A., De Simone C. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS. 11:1997;185-190
34. Feher J., Papale A., Mannino G., Gualdi L., Balacco Gabrieli C. Mitotropic compounds for the treatment of age-related macular degeneration. The metabolic approach and a pilot study. Ophthalmologica. 217:2003;351-357
35. Fernandez E., Pallini R., Lauretti L., La Marca F., Scogna A., Rossi G.F. Motonuclear changes after cranial nerve injury and regeneration. Arch. Ital. Biol. 135:1997;343-351
36. Genazzani E. A controlled clinical study on the efficacy of L-acetylcarnitine in the treatment of mild-to-moderate mental deterioration in the aged. Conclusions. Clin. Ter. 132:1990;511-512
37. Goety C.G., Tanner C.M., Cohen J.A., Thelen J.A., Carroll V.S., Klawans H.L., Fariello R.G. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov. Disord. 5:1990;263-265
38. Herrmann W.M., Dietrich B., Hiersemenzel R. Pharmaco- electroencephalographic and clinical effects of the cholinergic substance - acetyl-L-carnitine - in patients with organic brain syndrome. Int. J. Clin. Pharmacol. Res. 10:1990;81-84
39. Hinerfeld D., Traini M.D., Weinberger R.P., Cochran B., Doctrow S.R., Harry J., Melov S. Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J. Neurochem. 88:2004;657-667
40. Hoppel C.L., Davis A.T. Inter-tissue relationships in the synthesis and distribution of carnitine. Biochem. Soc. Trans. 14:1988;673-674
41. Hulsmann W.C. Biochemical profile of propionyl-L-carnitine. Cardiovasc. Drugs Ther. 5:1991;7-9
42. Imam S.Z., Ali S.F. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation. Brain Res. 855:2000;186-191
43. Imperato A., Ramacci M.T., Angelucci L. Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci. Lett. 107:1989;251-255
44. Inano A., Sai Y., Nikaido H., Hasimoto N., Asano M., Tsuji A., Tamai I. Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm. Drug Dispos. 24:2003;357-365
45. Infante J.P., Huszagh V.A. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 468:2000;1-5
46. Kashiwagi A., Kanno T., Arita K., Ishisaka R., Utsumi T., Utsumi K. Suppression of T(3)- and fatty acid-induced membrane permeability transition by L-carnitine. Comp. Biochem. Physiol. B - Biochem. Mol. Biol. 130:2001;411-418
47. Kerner J., Hoppel C. Genetic disorders of carnitine metabolism and their nutritional management. Annu. Rev. Nutr. 18:1998;179-206
48. Kido Y., Tamai I., Ohnari A., Sai Y., Kagami T., Nezu J., Nikaido H., Hashimoto N., Asano M., Tsuji A. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J. Neurochem. 79:2001;959-969
49. Kim C.S., Roe C.R., Ambrose W.W. L-Carnitine prevents mitochondrial damage induced by octanoic acid in the rat choroids plexus. Brain Res. 536:1990;335-338
50. Kim S.H., Vlkolinsky R., Cairns N., Lubec G. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol. Life Sci. 57:2000;1810-1816
51. Kimura S., Amemiya F. Brain and liver pathology in a patient with carnitine deficiency. Brain Dev. 12:1990;436-439
52. Kotake Y., Ohta S. MPP+ analogs acting on mitochondria and inducing neuro-degeneration. Curr. Med. Chem. 10:2003;2507-2516
53. Kumaran S., Deepak B., Naveen B., Panneerselvam C. Effects of levocarnitine on mitochondrial antioxidant systems and oxidative stress in aged rats. Drugs R. D. 4:2003;141-147
54. Liu J., Atamna H., Kuratsune H., Ames B.N. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann. N.Y. Acad. Sci. 959:2002;133-166
55. Lino A., Boccia M.M., Rusconi A.C., Bellomonte L., Cocuroccia B. Psycho functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration. Clin. Ter. 140:1992;569-573
56. Lowitt S., Malone J.I., Salem A., Kozak W.M., Orfalian Z. Acetyl-L-carnitine corrects electroretinographic deficits in experimental diabetes. Diabetes. 42:1993;1115-1118
57. Manfridi A., Forloni G.L., Arrigoni-Martelli E., Mancia M. Culture of dorsal root ganglion neurons from aged rats: effects of acetyl-L-carnitine and NGF. Int. J. Dev. Neurosci. 10:1992;321-329
58. Mazzio E., Yoon K.J., Soliman K.F. Acetyl-L-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells. Biochem. Pharmacol. 66:2003;297-306
59. Mezzina C., De Grandis D., Calvani M., Marchionni A., Pomes A. Idiopathic facial paralysis: new therapeutic prospects with acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 12:1992;299-304
60. Montgomery S.A., Thal L.J., Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 18:2003;61-71
61. Murakami K., Sugimoto T., Nishida N., Woo M., Araki A., Kobayashi Y. Alterations of urinary acetylcarnitine in valproate-treated rats: the effect of L-carnitine supplementation. J. Child Neurol. 7:1992;404-407
62. Nalecz K.A., Nalecz M.J. Carnitine - a known compound, a novel function in neural cells. Acta Neurobiol. Exp. (Wars.). 56:1996;597-609
63. Ori C., Freo U., Pizzolato G., Dam M. Effects of acetyl-L-carnitine on regional cerebral glucose metabolism in awake rats. Brain Res. 951:2002;330-335
64. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol. Aging. 16:1995;1-4
65. Puca F.M., Genco S., Specchio L.M., Brancasi B., D'Ursi R., Prudenzano A., Miccoli A., Scarcia R., Martino R., Savarese M. Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease. Int. J. Clin. Pharmacol. Res. 10:1990;139-143
66. Prickaerts J., Blokland A., Honig W., Meng F., Jolles J. Partial discrimination learning and choline acetyltransferase activity in streptozotocin-treated rats: effects of chronic treatment with acetyl-L-carnitine. Brain Res. 674:1995;142-146
67. Rosadini G., Marenco S., Nobili F., Novellone G., Rodriguez G. Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischaemia. Int. J. Clin. Pharmacol. Res. 10:1990;123-128
68. Salvioli G., Nerim M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp. Clin. Res. 20:1994;169-176
69. Santarelli M., Granato A., Sbriccoli A., Gobbi G., Janiri L., Minciacchi D. Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine. Brain Res. 698:1995;241-247
70. Schapira A.H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta. 1410:1999;159-170
71. Seven M., Cengiz M., Tuzgen S., Iscan M.Y. Plasma carnitine levels in children with Down syndrome. Am. J. Human Biol. 13:2001;721-725
72. Seidman M.D., Khan M.J., Bai U., Shirwany N., Quirk W.S. Biologic activity of mitochondrial metabolites on aging and age-related hearing loss. Am. J. Otol. 21:2000;161-167
73. Shug A.L., Schmidt M.J., Golden G.T., Fariello R.G. The distribution and role of carnitine in the mammalian brain. Life Sci. 31:1982;2869-2874
74. Sinforiani E., Iannuccelli M., Mauri M., Costa A., Merlo P., Bono G., Nappi G. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. Int. J. Clin. Pharmacol. Res. 10:1990;69-74
75. Sorbi S., Forleo P., Fani C., Piacentini S. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin. Neuropharmacol. 23:2000;114-118
76. Stanley C.A. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv. Pediatr. 34:1987;59-88
77. Steffen V., Santiago M., de la Cruz C.P., Revilla E., Machado A., Cano J. Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: protection by acetyl-L-carnitine. Hum. Exp. Toxicol. 14:1995;865-871
78. Tanaka M., Nakamura F., Mizokawa S., Matsumura A., Matsumura K., Watanabe Y. Role of acetyl-L-carnitine in the brain: revealed by bioradiography. Biochem. Biophys. Res. Commun. 306:2003;1064-1069
79. Tein I. Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy. J. Child Neurol. 2002;17:3S57-82
80. Tein I., DeVivo D.C., Bierman F., Pulver P., De Meirleir L.J., Cvitanovic-Sojat L., Pagon R.A., Bertini E., Dionisi-Vici C., Servidei S., et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr. Res. 28:1990;247-255
81. Thal L.J., Calvani M., Amato A., Carta A. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology. 55:2000;805-810
82. Torrioli M.G., Vernacotola S., Mariotti P., Bianchi E., Calvani M., De Gaetano A., Chiurazzi P., Neri G. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am. J. Med. Genet. 87:1999;366-368
83. Trauner D.A., Adams H.R. Effects of therapeutic agents in a rabbit model of Reye syndrome. Pediatr. Neurol. 3:1987;158-161
84. Van Oudheusden L.J., Scholte H.R. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot. Essent. Fatty Acids. 67:2002;33-38
85. Virmani M.A., Krsmanovic L.Z., Stojilkovic S.S., Catt K.J. Stimulatory effects of L-acetylcarnitine on the pituitary-gonadal axis in female rats. Adashi E.Y., Mancuso S. Advances in Human Female Reproduction. Sereno Symposium Publication. vol. 73:1991;291-296 Raven Press
86. Virmani M.A., Conti R., Spadoni A., Rossi S., Arrigoni-Martelli E. L-Carnitine uptake into primary rat cortical cultures: interaction with GABA. Brain Res. Mol. Brain Res. 25:1994;105-112
87. Virmani M.A., Biselli R., Spadoni A., Rossi S., Corsico N., Calvani M., Fattorossi A., De Simone C., Arrigoni-Martelli E. Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res. 32:1995;383-389
88. Virmani M.A., Rossi S., Conti R., Spadoni A., Arrigoni-Martelli E., Calvani M. Structural, metabolic and ionic requirements for the uptake of L-carnitine by primary rat cortical cells. Pharm. Res. 33:1996;19-27
89. Virmani M.A., Caso V., Spadoni A., Rossi S., Russo F., Gaetani F. The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Ann. N.Y. Acad. Sci. 939:2001;162-178
90. Virmani A., Gaetani F., Imam S., Binienda Z., Ali S. The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann. N.Y. Acad. Sci. 965:2002;225-232
91. Virmani A., Gaetani F., Imam S., Binienda Z., Ali S. Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity. Ann. N.Y. Acad. Sci. 993:2003;197-207
92. +: partial protection of PC12 cells by acetyl-L-carnitine. Ann. N.Y. Acad. Sci
93. Visentin M., Bellasio R., Tacconi M.T. Reye syndrome model in rats: protection against liver abnormalities by L-carnitine and acetyl-L-carnitine. J. Pharmacol. Exp. Ther. 275:1995;1069-1075
94. Wainwright M.S., Mannix M.K., Brown J., Stumpf D.A. L-Carnitine reduces brain injury after hypoxia-ischemia in newborn rats. Pediatr. Res. 54:2003;688-695
95. Wawrzenczyk A., Sacher A., Mac M., Nalecz M.J., Nalecz K.A. Transport of L-carnitine in isolated cerebral cortex neurons. Eur. J. Biochem. 268:2001;2091-2098
96. Wu X., Huang W., Prasad P.D., Seth P., Rajan D.P., Leibach F.H., Chen J., Conway S.J., Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J. Pharmacol. Exp. Ther. 290:1999;1482-1492